SAN DIEGO, Sept. 24, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will be included in the Russell 2000®, Russell 3000® and Russell Global Indices, effective Monday, September 30, 2013. The addition of Conatus is due to the quarterly adjustment of the Russell indices to account for initial public offerings.
Help employers find you! Check out all the jobs and post your resume.
